人民财讯9月2日电，东芯股份(688110)9月2日晚间公告，近期，公司就股票交易风险的相关事项进行了 核查。鉴于相关核查工作已完成，经申请，公司股票将9月3日开市起复牌。 ...

Core Viewpoint - Dongxin Co., Ltd. is making strategic investments in Shanghai Lishuan Technology Co., Ltd. to enhance its core competitiveness and create more value for its business and shareholders [2] Group 1: Investment in Shanghai Lishuan - Dongxin Co., Ltd. plans to invest approximately 50 million yuan in Shanghai Lishuan, with the company contributing about 21.05 million yuan to increase its stake to approximately 35.87% [2] - The investment will involve collaboration with Hengtong Group Co., Ltd., a fund managed by Shanghai Daohua Long-term Investment Management Co., Ltd., and other investors [2] - The completion of this investment is subject to shareholder approval and the finalization of investment agreements, which may lead to changes in shareholding ratios [2] Group 2: Product Development and Market Risks - Shanghai Lishuan has launched its first self-developed GPU chip "7G100" and graphics card product LisuaneXtreme, targeting applications in personal computers, professional design, cloud gaming, and digital twins [1] - The products are still in the process of certification, customer onboarding, and mass production, which introduces uncertainties regarding revenue generation [1] - The company faces various risks, including industrialization progress, market competition, product singularity, performance, ongoing operations, and cash flow [1] Group 3: Stock Trading and Regulatory Updates - Dongxin Co., Ltd. has completed a review of stock trading risks and has applied for the resumption of its stock trading, set to resume on September 3, 2025 [3]

东芯股份公告，公司股票将于2025年9月3日开市起复牌。公司股票价格自2025年7月29日以来多次触及 股票交易异常波动及严重异常波动情形。公司已发布5次异常波动、严重异常波动、交易风险提示公 告，提示股票交易风险。公司股价累计涨幅为207.85%，显著高于上证综指、科创50、科创100等相关 指数涨幅。公司股票交易平均换手率为11.77%，显著高于前期换手率水平。公司滚动市盈率为53.35， 目前公司滚动市盈率为负数。公司2025年上半年实现营业收入3.43亿元，同比增加28.81%；归属于上市 公司股东的净利润-1.11亿元，同比亏损金额增加1984.74万元；归属于上市公司股东的扣除非经常性损 益的净利润-1.27亿元，同比亏损金额增加2739.98万元。 ...

Core Viewpoint - Dongxin Co., Ltd. is making strategic investments in Shanghai Lishuan Technology Co., Ltd. to enhance its core competitiveness and create more value for its business and shareholders [2] Group 1: Investment in Shanghai Lishuan - Dongxin Co., Ltd. plans to invest approximately 50 million yuan in Shanghai Lishuan, with the company contributing about 21.05 million yuan to increase its stake to approximately 35.87% [2] - The investment will involve collaboration with Hengtong Group Co., Ltd., a fund managed by Shanghai Daohua Long-term Investment Management Co., Ltd., and other investors [2] - The completion of this investment is subject to shareholder approval and the finalization of investment agreements, which may lead to changes in shareholding ratios [2] Group 2: Product Development and Market Risks - Shanghai Lishuan has launched its first self-developed GPU chip "7G100" and graphics card product LisuaneXtreme, targeting applications in personal computers, professional design, cloud gaming, and digital twins [1] - The products are still in the process of certification, customer onboarding, and mass production, which introduces uncertainties regarding revenue generation [1] - The company faces various risks including industrialization progress, market competition, product singularity, performance, ongoing operations, and cash flow [1] Group 3: Stock Trading and Regulatory Updates - Dongxin Co., Ltd. has completed a review of stock trading risks and has applied for the resumption of its stock trading, set to resume on September 3, 2025 [3]

Core Viewpoint - Dongxin Co., Ltd. announced an investment in Shanghai Lishuan Technology Co., Ltd. with a pre-investment valuation of 3.5 billion yuan, aiming to enhance its strategic layout in the integrated "storage, computing, and networking" sector [2][11]. Investment Details - Dongxin plans to invest approximately 210.53 million yuan to acquire about 80.99 million yuan of new registered capital in Shanghai Lishuan, resulting in a 35.87% ownership stake post-investment [5][11]. - The total investment amount from all investors is around 500 million yuan, with the investment price set at 259.95 yuan per 1 yuan of registered capital [2][5]. Company Background - Shanghai Lishuan was established on April 26, 2022, with a registered capital of 13.464 million yuan, focusing on the research and design of scalable GPU chips for graphics rendering and AI acceleration [6][8]. - The company has not generated revenue yet, with total assets of 34.34 million yuan and total liabilities of 121 million yuan as of July 2023, resulting in a net asset deficit of 86.33 million yuan [9][10]. Financial Performance - For the fiscal year 2024, Shanghai Lishuan is projected to incur a net loss of 210 million yuan, with a loss of 155 million yuan recorded from January to July 2025 [9][10]. - The company's financials indicate a significant increase in liabilities compared to assets, highlighting potential financial challenges [9][10]. Strategic Implications - The investment is part of Dongxin's strategy to strengthen its core competitiveness and create more value for shareholders, while Shanghai Lishuan remains a non-consolidated subsidiary [11].

财经图解 . 财经大事早知道，关注东方财富股票！ 以下文章来源于财经图解 ，作者止于月影 涨幅超 400% 长城军工 488.18% 北方长龙 448.01% 仕佳光子 407.29% 宏和科技 406.47% 涨幅超 300% | 菲林格尔 390.70% 东芯股份 373.90% 塞力医疗 370.22% | | --- | | 隆扬电子 362.76% 联合化学 352.60% 新易盛 333.20% | | 浙海德曼 331.81% 浙江东日 328.54% 思泉新材 328.20% | | *ST 亚振 318.43% | 涨幅超 200% | 宏景科技 恒宝股份 | 一品红 汇金股份 | | 天普股份 | 昂利康 | | --- | --- | --- | --- | --- | | 奇德新材 | ST 信通 中旗新材 | 鼎泰高科 | 南亚新材 | 开普云 | | 浙江荣泰 | 赛诺医疗 | | 热景生物 | 科思科技 | | 九菱科技 | 若羽臣 戈碧迦 | 天臣医疗 | 中洲特材 | 华胜天成 | | 恒立钻具 | 博瑞医药 | 中环海陆 | 一致魔芋 | 中大力德 | | 上海洗霸 | 华 ...

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

登录新浪财经APP 搜索【信披】查看更多考评等级 专题：专题：第十一届金麒麟·金牌董秘荣誉榜单揭晓！ 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月1日，第十一届新浪财经金麒麟·金牌董秘榜单正式揭晓。在本次备受瞩目的评选中，东芯股份董事 会秘书蒋雨舟凭借卓越的专业能力和出色的工作表现荣耀加冕，荣获第十一届金麒麟·金牌董秘责任先 锋奖。 作为上市公司与资本市场之间的"关键纽带"，董秘在企业治理与发展中扮演着多重角色：他们既是公司 规范运作的"守门人"，也是资本战略的"参谋者"；既是信息披露的"发言人"，也是投资者关系的"架构 师"。秉持"寻找A股最佳资本品牌代言人"的初心，新浪财经金麒麟·金牌董秘评选已成功举办十一届， 累计评选出优秀金牌董秘900余人次，成为业内高度认可、影响力广泛的权威奖项之一。该评选不仅着 眼于信息披露质量、投资者沟通成效，更综合考量其在公司治理、ESG建设、资本运作等多维度的贡 献。 一位优秀的董秘，能在复杂的市场环境中精准传递公司价值，在合规底线之上创新沟通方式，更能在关 键时刻展现企业的责任与担当。他们以专业、透明、高效的沟通，构建起企业与投资者、监管 ...

Core Viewpoint - Dongxin Co., Ltd. announced an investment of approximately 500 million yuan in Lishuan Technology (Shanghai) Co., Ltd., with Dongxin contributing about 211 million yuan to acquire a 35.87% stake, aiming to enhance its integrated strategy in storage, computing, and networking [1] Group 1: Investment Details - The total investment amount for the project is around 500 million yuan, with Dongxin's investment being approximately 211 million yuan [1] - After the capital increase, Dongxin will hold about 35.87% of Lishuan Technology [1] Group 2: Business Focus and Risks - Lishuan Technology primarily focuses on the research and development of scalable GPU chips for graphics rendering, which are designed to compete with mainstream GPU architectures [1] - The company's revenue and profit are heavily reliant on the sales performance of its flagship "7G100" GPU product, posing a risk of dependency on a single product [2] - Financial data indicates that Lishuan Technology has not generated revenue in 2024 and the first seven months of 2025, with losses of 210 million yuan and 155 million yuan respectively [2] Group 3: Dongxin's Financial Performance - Dongxin Co., Ltd. was listed in December 2021 and has experienced a nearly 30% decline in net profit in its second year post-IPO, with consecutive losses in 2023 and 2024 [3] - For the first half of 2025, Dongxin reported a revenue of 343 million yuan, a year-on-year increase of 28.81%, but a net loss of 111 million yuan, down 21.78% year-on-year [3] - The stock price of Dongxin has seen a significant increase of 207.85% from July 29 to August 28, 2023, leading to trading suspensions due to abnormal fluctuations [3]

Core Viewpoint - Dongxin Co., Ltd. (688110.SH) has announced a new financing round of 500 million yuan for its affiliate, Lixuan Technology (Shanghai) Co., Ltd., with Dongxin contributing approximately 210 million yuan, becoming the largest shareholder with a 35.87% stake [1][4]. Group 1: Financing and Ownership - Lixuan Technology's pre-investment valuation has increased from 200 million yuan in the previous round to 3.5 billion yuan currently [1]. - Dongxin previously invested 200 million yuan in Lixuan Technology to help it out of a financial crisis, appointing board members and a financial director while allowing the original management team to handle daily operations [1][4]. Group 2: Product Development - Lixuan Technology launched its first GPU chip, the 7G100 series, on July 26, aimed at applications such as personal computers, professional design, cloud gaming, and digital twins [1][3]. - The 7G100 series is designed entirely in-house and supports various computing tasks, including single-precision and half-precision floating-point operations, as well as 8-bit integer operations [3]. Group 3: Financial Performance and Risks - Lixuan Technology has reported zero revenue for 2023, 2024, and the first seven months of 2025, with cumulative losses of approximately 510 million yuan [4]. - The company faces significant financial pressure, with total liabilities of about 120 million yuan as of July 31, 2025, and requires continuous funding for R&D to keep up with market demands [4].